Showing results (181-190 of 1,869) with videos related to
Sort By:
Pageof 187
Current Cancer Drug Targets|April 13, 2018
Role of MicroRNAs in Treatment Response in Prostate CancerAnshuli Razdan, Paul de Souza, Tara Laurine RobertsCurrent Cancer Drug Targets|May 3, 2017
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular CarcinomaNabiel Mir, Aparna Jayachandran, Bijay Dhungel, et al.Current Cancer Drug Targets|May 3, 2017
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell DeathElisa Mandato, Sara Canovas Nunes, Fortunato Zaffino, et al.Current Cancer Drug Targets|July 4, 2017
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung CancerDhaval Sanchala, Lokesh K Bhatt, Kedar S PrabhavalkarCurrent Cancer Drug Targets|July 4, 2017
Synthetic Lethality: From Research to Precision Cancer NanomedicineAnuradha Gupta, Anas Ahmad, Aqib Iqbal Dar, et al.Current Cancer Drug Targets|July 4, 2017
DNA Fragmentation, Cell Cycle Arrest, and Docking Study of Novel Bis Spiro-cyclic 2-oxindole of Pyrimido[4,5-b]quinoline-4,6-dione Derivatives Against Breast CarcinomaMagda F Mohamed, Amr Mohamed Abdelmoniem, Ahmed H M Elwahy, et al.Current Cancer Drug Targets|July 4, 2017
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma CellsIlaria Zanellato, Donato Colangelo, Domenico OsellaCurrent Cancer Drug Targets|July 4, 2017
Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in CancerNoreen Akhtar, Ishrat JabeenCurrent Cancer Drug Targets|July 4, 2017
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer AgentsSurendra Kumar Nayak, Gopal L Khatik, Rakesh Narang, et al.Current Cancer Drug Targets|July 4, 2017
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic AgentsLeila Farahmand, Parnaz Merikhian, Neda Jalili, et al.Pageof 187